| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/23/2003 | CA2453175A1 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | CA2453027A1 Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| 01/23/2003 | CA2452610A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | CA2452513A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound |
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2452417A1 Compositions comprising the biologicially active peptide ysl |
| 01/23/2003 | CA2451566A1 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | CA2450898A1 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/23/2003 | CA2449504A1 Bridged bicyclic serine protease inhibitors |
| 01/23/2003 | CA2448814A1 Composition for sustained release injections and production method thereof |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/22/2003 | EP1277843A2 Novel human genes and gene expression products related to colon cancer |
| 01/22/2003 | EP1277754A1 Imidazopyridine derivatives |
| 01/22/2003 | EP1277747A1 Selective preventives/remedies for progressive lesions after organ damage |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277738A1 Condensed heteroaryl derivatives |
| 01/22/2003 | EP1277737A1 Diphenylalkylamine derivatives useful as opioid delta receptor agonists |
| 01/22/2003 | EP1277736A1 Novel bicyclic compounds |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277476A1 Utilization of adamts-1 protein and method of screening aggrecanase activity regulator |
| 01/22/2003 | EP1277473A1 Remedies |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1277469A1 Activators for peroxisome proliferator-activated receptor |
| 01/22/2003 | EP1276887A2 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors |
| 01/22/2003 | EP1276880A2 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276750A1 Antisense modulation of zinc finger protein-217 expression |
| 01/22/2003 | EP1276749A1 Novel, photo-labile cumarinylmethyl esters of cyclic nucleotides, method for the production and use thereof |
| 01/22/2003 | EP1276740A2 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276737A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| 01/22/2003 | EP1276736A2 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| 01/22/2003 | EP1276726A2 Substituted phenyl farnesyltransferase inhibitors |
| 01/22/2003 | EP1276725A2 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276724A2 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276722A1 Naphthamidine urokinase inhibitors |
| 01/22/2003 | EP1276720A2 2-acyl indol derivatives and their use as anti-tumour agents |
| 01/22/2003 | EP1276714A2 Cyclic carboxylic acids as integrin antagonists |
| 01/22/2003 | EP1276713A1 Inhibition of angiogenesis and tumor growth |
| 01/22/2003 | EP1276503A2 Compositions comprising an inhibitor of an acrab-like efflux pump for reducing microbial resistance to drugs |
| 01/22/2003 | EP1276497A2 Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors |
| 01/22/2003 | EP1276496A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 01/22/2003 | EP1276494A1 A memory enhancing protein |
| 01/22/2003 | EP1276491A1 Tamandarin and didemnin analogs and methods of making and using them |
| 01/22/2003 | EP1276487A1 Treatment of conditions of the central nervous system using mycobacteria |
| 01/22/2003 | EP1276485A2 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate |
| 01/22/2003 | EP1276482A2 Combination chemotherapy |
| 01/22/2003 | EP1276481A2 Daily treatment for erectile dysfunction using a pde5 inhibitor |
| 01/22/2003 | EP1276478A2 (2-aminoethyl) oxime derivatives for the treatment of depression |
| 01/22/2003 | EP1276476A2 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 01/22/2003 | EP1276471A2 Membrane delivery system |
| 01/22/2003 | EP1222459A4 Crystallographic structure of the androgen receptor ligand binding domain |
| 01/22/2003 | EP1107980B1 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH |
| 01/22/2003 | EP1084129B1 Cyclic boroproline compounds |
| 01/22/2003 | EP1017405A4 Therapeutic hemoglobin composition having isotropically increased size |
| 01/22/2003 | EP0973901B1 Flip gene and flip protein |
| 01/22/2003 | EP0942721B1 Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid |
| 01/22/2003 | EP0909174A4 Treatment of cystic disease with tnf-alpha |
| 01/22/2003 | EP0898562B1 Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation |
| 01/22/2003 | EP0828728B1 Phenyl dihydrobenzofuranes |
| 01/22/2003 | EP0728009B1 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier |
| 01/22/2003 | EP0646115B1 Heterocyclic-cyclic amine derivatives |
| 01/22/2003 | CN1392875A Condensed azepines as vasopressino agonists |
| 01/22/2003 | CN1392874A Cyclic amidine compounds |
| 01/22/2003 | CN1392798A Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides, and vaccine composition comprising same |
| 01/22/2003 | CN1392795A Novel tiotropiumonium-containing inhalation powder |
| 01/22/2003 | CN1391933A Medicinal composition for improving memory |
| 01/22/2003 | CN1391919A Lifuji oral liquor |
| 01/22/2003 | CN1391913A Oral liquid against noise and its preparing method |
| 01/22/2003 | CN1391901A Injection for curing hemangioma |
| 01/22/2003 | CN1391880A Electric moxibustion instrument |
| 01/22/2003 | CN1099425C 新的肽衍生物 New peptide derivatives |
| 01/22/2003 | CN1099419C Azebicyclic compound |
| 01/22/2003 | CN1099413C Certain fused N-pyrrolylaniline: new class of GABA brain receptor ligand |
| 01/22/2003 | CN1099284C Aryloxy propyl amine compound for treatment of incontinence of urine |
| 01/21/2003 | US6509499 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment |
| 01/21/2003 | US6509466 Reacting 17 beta-(alkoxycarbonyl)-3-one-4-aza-steroid with lithium tert-butylamide in an organic solvent |
| 01/21/2003 | US6509464 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509371 Compositions containing Bergamottin for increasing the oral bioavailability of pharmaceutical agents |
| 01/21/2003 | US6509368 Use of catechol derivatives as proteinase inhibitors |
| 01/21/2003 | US6509365 Useful as inhibitors of poly(ADP-ribose)polymerase and for the production of drugs. |
| 01/21/2003 | US6509364 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2α antagonists |
| 01/21/2003 | US6509363 P38 is a mitogen-activated protein kinase; pyrrole, oxazole, thiazole, and imidazole derivatives |
| 01/21/2003 | US6509357 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/21/2003 | US6509355 Treatment of disorders of the outer retina |
| 01/21/2003 | US6509351 A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation |
| 01/21/2003 | US6509346 Chemokine receptor antagonists and methods of use therefor |
| 01/21/2003 | US6509341 The invention relates to carboxylic acid derivatives of formula (I), wherein the substituents have the meaning as commented in the description. It also relates to the production and use of same as endothelin receptor antagonists. |
| 01/21/2003 | US6509340 Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT1B/1D ligands |
| 01/21/2003 | US6509335 This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of |
| 01/21/2003 | US6509334 Cyclocarbamate derivatives as progesterone receptor modulators |
| 01/21/2003 | US6509329 Cyclic diamine compound with 6-membered ring groups |
| 01/21/2003 | US6509328 Glutamate receptor antagonists |
| 01/21/2003 | US6509326 Supplements are useful for increasing bone growth and treating age-related bone loss |
| 01/21/2003 | US6509318 TGF-B inhibitors and methods |